New drug for returning multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma that has come back or did not respond to treatment.
- You have already tried at least two different treatment plans, including a proteasome inhibitor (such as bortezomib), an immunomodulatory drug (such as lenalidomide), and a CD38-targeting antibody (such as daratumumab).
- Your disease is measurable, meaning you have a certain level of M protein or free light chains in your blood or urine.
- You are generally able to care for yourself (ECOG performance status 0-2).
- You have not been treated with a BCMA-targeting therapy, and you have not had CAR-T or CAR-NK cell therapy in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called QI-019B for people with multiple myeloma whose cancer has come back or stopped responding to other treatments. The goal is to see if it is safe and can help shrink or slow the cancer.
This trial tests a new treatment combination for multiple myeloma that has returned or stopped responding to previous therapy and has spread outside the bone marrow. It aims to see if the combination can shrink these tumors and improve outcomes.
This study tests an experimental drug called RN9101 for people with multiple myeloma that has returned or stopped responding to other treatments. The drug targets a protein called BCMA found on myeloma cells, and the goal is to see if it is safe and can help control the disease.
This trial tests a new drug called QI-019A for people whose multiple myeloma has returned or stopped responding to at least two prior treatments. The goal is to see if it is safe and if it can help control the disease.
This study tests a new combination of drugs for people newly diagnosed with a high-risk form of multiple myeloma. The goal is to see if this combination is safe and works better than standard treatments.
This trial tests CM336, a new medicine, in people with multiple myeloma that has returned (relapsed) or not responded (refractory) to standard treatments. It may help by trying a different approach when other key medicines have already been tried.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.